BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28710606)

  • 1. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.
    Qiu H; Moravan MJ; Milano MT; Usuki KY; Katz AW
    J Gastrointest Cancer; 2018 Dec; 49(4):463-469. PubMed ID: 28710606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
    Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
    Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
    Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
    Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
    Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
    Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
    Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
    Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
    Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
    Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Kim DY; Han KH; Seong J
    Dig Liver Dis; 2019 Mar; 51(3):445-451. PubMed ID: 30503296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
    Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.